BOSTON—Amy Elazzouzi, Vice President of Finance at Aura Biosciences , Inc. (NASDAQ:AURA), not too long ago offered 1,001 shares of the corporate’s widespread inventory. The shares had been offered at a weighted common value of $7.6715, totaling roughly $7,679. The transaction comes as AURA trades at $7.93, with analysts setting a mean value goal of $20-23, suggesting vital upside potential in keeping with InvestingPro knowledge. This transaction was executed to cowl tax withholding obligations associated to the vesting of restricted inventory models. Following this sale, Elazzouzi holds 38,442 shares instantly. The sale was performed mechanically, not at Elazzouzi’s discretion, as a part of a pre-arranged plan. Aura Biosciences, a Boston-based biotechnology firm valued at $388 million, maintains a powerful liquidity place with a present ratio of 12.47 and more money than debt on its steadiness sheet. InvestingPro evaluation reveals 6 extra key insights about AURA’s monetary well being and development prospects.
This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.
Following experiences that Britons are going through extortionate calls for as a consequence of defective…
By Michael S. Derby NEW YORK (Reuters) -Federal Reserve officers talking in tv interviews on…
John Lewis's bank card accomplice has acquired expressions of curiosity in a takeover of elements…
Lisa Nandy, the tradition secretary, is to log out the appointment of a chair of…
Lisa Nandy, the tradition secretary, is to log off the appointment of a chair of…
By Karin Strohecker and David Lawder WASHINGTON (Reuters) -Rising economies should grapple with tighter international…